» Articles » PMID: 24692361

Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis

Overview
Specialty Rheumatology
Date 2014 Apr 3
PMID 24692361
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Skin and musculoskeletal involvement are frequently present early in diffuse cutaneous systemic sclerosis (dcSSc). The current study examined the correlates for skin and musculoskeletal measures in a 1-year longitudinal observational study.

Methods: Patients with dcSSc were recruited at 4 US centers and enrolled in a 1-year study. Prespecified and standardized measures included physician and patient assessments of skin involvement, modified Rodnan skin score (MRSS), durometer score, Health Assessment Questionnaire disability index, serum creatine phosphokinase, tender joint counts, and presence/absence of tendon friction rubs, small joint contractures, and large joint contractures. Additionally, physician and patient global health assessments and health-related quality of life assessments were recorded. Correlations were computed among the baseline global assessments, skin variables, and musculoskeletal variables. Using the followup physician and patient anchors, effect sizes were calculated.

Results: A total of 200 patients were studied: 75% were women, mean ± SD age was 50.0 ± 11.9 years, and mean ± SD disease duration from first non-Raynaud's phenomenon symptom was 1.6 ± 1.4 years. Physician global health assessment had large correlations with MRSS (r = 0.60) and physician-reported skin involvement visual analog scale in the last month (r = 0.74), whereas patient global assessment had large correlations with MRSS, the Short Form 36 health survey physical component scale, skin interference, and skin involvement in the last month (r = 0.37-0.72). Four of 9 skin variables had moderate to large effect sizes (0.51-1.09).

Conclusion: Physician and patient global assessments have larger correlations with skin measures compared to musculoskeletal measures. From a clinical trial perspective, skin variables were more responsive to change than musculoskeletal variables over a 1-year period, although both provide complementary information.

Citing Articles

Elastography as a possible useful method of assessment of skin involvement in systemic sclerosis.

Sobolewski P, Dzwigala M, Zakrzewski J, Paluch L, Bogucki J, Szymanska E Postepy Dermatol Alergol. 2022; 39(4):775-781.

PMID: 36090711 PMC: 9454354. DOI: 10.5114/ada.2021.109503.


The challenges and controversies of measuring disease activity in systemic sclerosis.

Ross L, Baron M, Nikpour M J Scleroderma Relat Disord. 2022; 3(2):115-121.

PMID: 35382236 PMC: 8892866. DOI: 10.1177/2397198318765061.


Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Pauling J, Caetano J, Campochiaro C, Luca G, Gheorghiu A, Lazzaroni M J Scleroderma Relat Disord. 2022; 5(2):90-102.

PMID: 35382020 PMC: 8922614. DOI: 10.1177/2397198319886496.


Validation of Sonography findings of synovitis and tenosynovitis of hands and wrists in patients with systemic sclerosis.

Scheiman-Elazary A, Ranganath V, Ben-Artzi A, Kafaja S, Borazan N, Woodworth T J Scleroderma Relat Disord. 2022; 3(3):228-236.

PMID: 35382015 PMC: 8922605. DOI: 10.1177/2397198318774301.


Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.

Khanna D, Spino C, Johnson S, Chung L, Whitfield M, Denton C Arthritis Rheumatol. 2019; 72(1):125-136.

PMID: 31342624 PMC: 6935399. DOI: 10.1002/art.41055.


References
1.
Cole J, Khanna D, Clements P, Seibold J, Tashkin D, Paulus H . Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res. 2006; 15(8):1383-94. DOI: 10.1007/s11136-006-0018-8. View

2.
Khanna D, Clements P, Furst D, Korn J, Ellman M, Rothfield N . Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009; 60(4):1102-11. PMC: 3711466. DOI: 10.1002/art.24380. View

3.
Fries J, Spitz P, Kraines R, HOLMAN H . Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2):137-45. DOI: 10.1002/art.1780230202. View

4.
Khanna P, Furst D, Clements P, Maranian P, Indulkar L, Khanna D . Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology (Oxford). 2010; 49(5):955-9. PMC: 2909791. DOI: 10.1093/rheumatology/kep464. View

5.
Medsger Jr T, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W . Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003; 21(3 Suppl 29):S42-6. View